Vaccination with an anti-CEA can break immune tolerance to TAA CEA and induce anti-CEA antibodies as well as CEA-specific CD4+ T-helper responses in colon cancer patients and mice transgenic for human CEA (193). Here, CEACAM5 is linked to malignant colon neoplasm.